II Ivivi Technologies, Inc.

Ivivi Technologies, Inc. (AMEX:II), a developer of non-invasive, electrotherapeutic technologies, today announced that Barrie, Ontario-based T.H.E. Medical, Ivivi�s exclusive Canadian distributor, has obtained approval from Health Canada, Canada�s Federal regulatory department for health matters, for the distribution of Ivivi�s Roma3 pulsed electromagnetic field (PEMF) therapy device in Canada. Roma3 represents Ivivi�s latest technological advancement in Electroceuticals� and will now be available in Canada for the non-invasive treatment of pain and edema in wounds. �We believe the market for wound care products in Canada, like the rest of the world, will continue to grow, driven by an aging population as well as the rise in the incidence of diabetes. We are delighted that healthcare providers and patients in Canada will now be able to benefit from the Roma3,� said Andre� DiMino, Vice Chairman and Co-Chief Executive Officer of Ivivi. �Our PEMF technology has been safely used in over 600,000 treatments since the mid 1990�s to non-invasively treat injured soft tissue pain and swelling by stimulating biochemical and physiological processes.� "We are very excited to bring this next generation wound care technology to Canada. The Roma3 has shown excellent clinical outcomes while drastically lowering the cost-per-treatment when compared to other technologies currently available,� said Noel Duquette, Co-Chair of T.H.E. Medical. "We were drawn to T.H.E. Medical because of their fine reputation and ability to educate, sell and support the platform across the country,� added DiMino. �T.H.E Medical has demonstrated both the vision and capacity to bring our technology to a large clinical population,� said David Saloff, President and Co-CEO of Ivivi. �We believe this is an excellent opportunity to make a difference in the lives of many Canadians, without many of the risks associated with other therapies.� The Roma3 is primarily marketed as a rental product to the chronic care markets, particularly for use in long-term acute care hospitals, as well as in long-term care nursing facilities, rehabilitation hospitals, acute care hospitals and facilities and home health systems. About Ivivi Technologies, Inc. Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi�s research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological processes to help repair injured tissue and reduce related pain and inflammation. The Company�s Electroceuticals� have been used in non-invasive treatments for a wide array of conditions, including pain and edema in chronic wounds, plastic and reconstructive surgery and chronic inflammatory disorders. For more information visit www.ivivitechnologies.com. About T.H.E. Medical Based in Barrie-Ontario, T.H.E. Medical, established in 1989, is the leading Canadian manufacturer of high-quality, full-line institutional patient care and patient handling products. For more information visit www.themedical.com. Forward-Looking Statements This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company�s limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company�s products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company�s intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company�s products and other risks detailed from time to time in the Company�s filings with the Securities and Exchange Commission, including the Company�s registration statement on Form SB-2. The Company assumes no obligation to update the information contained in this press release.